At a glance
ClinicalIndex Comparison RecordN/ACompleted· 11 enrolled
Drug / intervention
Quick Bolus +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Insulin Bolus Speed of Rapid-Acting Insulin Analog Absorption and Action in Individuals With Type 1 Diabetes
In Brief
A clinical study evaluating Quick Bolus and Standard Bolus for Type1diabetes. Completed, enrolled 11 participants across 1 site.
Detailed Summary
Rapid Action Insulin (RAI) absorption and action measured by time to reach maximum insulin concentration and glucose infusion rate.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType1diabetes
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartMay 2018
First PostedMay 2018
Primary CompletionSep 2022
TodayJul 2026
First PostedMay 31, 2018
Enrollment StartMay 30, 2018
Primary CompletionSep 23, 2022
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 8.1 years ago
Interventions
Quick Bolusdevice
Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via "quick bolus" of 15 units per minute during a euglycemic clamp.
Standard Bolusdevice
Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via "standard bolus" of 1.5 units per minute during a euglycemic clamp.